Shengjun Wang

Array ( [id] => 10421055 [patent_doc_number] => 20150306066 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-29 [patent_title] => 'TREATMENT OF HUMAN CYTOMEGALOVIRUS BY MODULATING WNT' [patent_app_type] => utility [patent_app_number] => 14/678128 [patent_app_country] => US [patent_app_date] => 2015-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 14256 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14678128 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10311638 [patent_doc_number] => 20150196640 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-16 [patent_title] => 'PROGESTERONE FORMULATIONS HAVING A DESIRABLE PK PROFILE' [patent_app_type] => utility [patent_app_number] => 14/671655 [patent_app_country] => US [patent_app_date] => 2015-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 24141 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14671655 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10311613 [patent_doc_number] => 20150196615 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-16 [patent_title] => 'Methods for Treating HCV' [patent_app_type] => utility [patent_app_number] => 14/670734 [patent_app_country] => US [patent_app_date] => 2015-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 59216 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14670734 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11704534 [patent_doc_number] => 20170173033 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-22 [patent_title] => 'PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 15/128714 [patent_app_country] => US [patent_app_date] => 2015-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 26915 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15128714 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10669531 [patent_doc_number] => 20160015673 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-21 [patent_title] => 'METHOD FOR LOWERING CHOLESTEROL' [patent_app_type] => utility [patent_app_number] => 14/663440 [patent_app_country] => US [patent_app_date] => 2015-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 33328 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14663440 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13328343 [patent_doc_number] => 20180215709 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-02 [patent_title] => TYPE III DEIODINASE INHIBITORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/126023 [patent_app_country] => US [patent_app_date] => 2015-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11500 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15126023 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11203996 [patent_doc_number] => 09433607 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-09-06 [patent_title] => 'Composition for prevention or treatment of cancer comprising N-methylenenaphtho[2,1-b]furan-2-carbohydrazide derivatives as an active ingredient' [patent_app_type] => utility [patent_app_number] => 14/641065 [patent_app_country] => US [patent_app_date] => 2015-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 10295 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14641065 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10489694 [patent_doc_number] => 20150374715 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-31 [patent_title] => 'EP2 AND EP4 AGONISTS AS AGENTS FOR THE TREATMENT OF INFLUENZA A VIRAL INFECTION' [patent_app_type] => utility [patent_app_number] => 14/634445 [patent_app_country] => US [patent_app_date] => 2015-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7634 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14634445 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10279980 [patent_doc_number] => 20150164976 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-18 [patent_title] => 'Methods for Treating HCV' [patent_app_type] => utility [patent_app_number] => 14/628849 [patent_app_country] => US [patent_app_date] => 2015-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 63000 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14628849 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10339093 [patent_doc_number] => 20150224099 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-13 [patent_title] => 'ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS' [patent_app_type] => utility [patent_app_number] => 14/622700 [patent_app_country] => US [patent_app_date] => 2015-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 16516 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14622700 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10331868 [patent_doc_number] => 20150216873 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-06 [patent_title] => 'METHODS OF TREATING PATIENTS CO-INFECTED WITH HIV AND TUBERCULOSIS' [patent_app_type] => utility [patent_app_number] => 14/614133 [patent_app_country] => US [patent_app_date] => 2015-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4773 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14614133 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11262160 [patent_doc_number] => 09486442 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-08 [patent_title] => 'Methods for treating or preventing brain infections' [patent_app_type] => utility [patent_app_number] => 14/612773 [patent_app_country] => US [patent_app_date] => 2015-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 27 [patent_no_of_words] => 24231 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14612773 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10121384 [patent_doc_number] => 09155731 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2015-10-13 [patent_title] => 'Methods of non-gastrointestinal endoscopic procedures using L-hyoscyamine oral formulations' [patent_app_type] => utility [patent_app_number] => 14/611635 [patent_app_country] => US [patent_app_date] => 2015-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3952 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14611635 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10234443 [patent_doc_number] => 20150119437 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-30 [patent_title] => 'Methods of Treating Cognitive Dysfunction by Modulating Brain Energy Metabolism' [patent_app_type] => utility [patent_app_number] => 14/593461 [patent_app_country] => US [patent_app_date] => 2015-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 7657 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14593461 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11858919 [patent_doc_number] => 09738591 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-08-22 [patent_title] => 'Antimicrobial compounds' [patent_app_type] => utility [patent_app_number] => 14/592629 [patent_app_country] => US [patent_app_date] => 2015-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 20 [patent_no_of_words] => 16255 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14592629 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11129166 [patent_doc_number] => 20160326141 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-10 [patent_title] => 'HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS FOR USE AGAINST CANCER AND VIRAL INFECTIONS' [patent_app_type] => utility [patent_app_number] => 15/110154 [patent_app_country] => US [patent_app_date] => 2015-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20995 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15110154 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10225771 [patent_doc_number] => 20150110764 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-23 [patent_title] => 'Food-Induced Antisecretory Proteins' [patent_app_type] => utility [patent_app_number] => 14/589235 [patent_app_country] => US [patent_app_date] => 2015-01-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2589 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14589235 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10226968 [patent_doc_number] => 20150111961 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-23 [patent_title] => 'MEMBRANE FUSION INHIBITOR' [patent_app_type] => utility [patent_app_number] => 14/581543 [patent_app_country] => US [patent_app_date] => 2014-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 14529 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14581543 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14243829 [patent_doc_number] => 10272097 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-30 [patent_title] => Uses of oxygenated cholesterol sulfates (OCS) [patent_app_type] => utility [patent_app_number] => 15/106883 [patent_app_country] => US [patent_app_date] => 2014-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 24 [patent_no_of_words] => 21516 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15106883 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14697569 [patent_doc_number] => 10376506 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-08-13 [patent_title] => Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features [patent_app_type] => utility [patent_app_number] => 15/105701 [patent_app_country] => US [patent_app_date] => 2014-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 9576 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15105701 [rel_patent_id] =>[rel_patent_doc_number] =>)